Ground Swell Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Ground Swell Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$55K	Buy	+329	New	+$54K	0.1%	192

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ground Swell Capital's ALXN Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Alexion Pharmaceuticals (ALXN) in Q3 2014: 329 shares worth $55K. The stake represents 0.1% of the portfolio and ranks #192 among its holdings.

521 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

Ground Swell Capital held 329 shares of Alexion Pharmaceuticals worth $55K as of Q3 2014.
Alexion Pharmaceuticals was a new Ground Swell Capital position in Q3 2014.
Alexion Pharmaceuticals made up 0.1% of Ground Swell Capital's portfolio in Q3 2014, its #192 holding.
521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.